Post-transplantation antibody monitoring and HLA antibody epitope identification

Current Opinion in Immunology

Volumn 20, Issue 5, 2008, Pages 602-606

  Cai, Junchao ^a   Terasaki, Paul I ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; EPITOPE; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I RELATED CHAIN A; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIGEN BINDING; CHRONIC GRAFT REJECTION; DETERIORATION; GRAFT FAILURE; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; MONITORING; ORGAN TRANSPLANTATION; RECIPIENT; REVIEW; RISK FACTOR; TECHNOLOGY;

EPITOPES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; MONITORING, IMMUNOLOGIC;

EID: 50549095803     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.07.008     Document Type: Review

References (37)

1. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 58 (1965) 295
2. Terasaki P.I., and Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation. 86 3 (2008) 377
3. Solez K., Colvin R.B., Racusen L.C., Haas M., Sis B., Mengel M., Halloran P.F., Baldwin W., Banfi G., Collins A.B., et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8 4 (2008) 753. Diagnostic categories of AMR have been updated.
4. Dickenmann M., Steiger J., Descoeudres B., Mihatsch M., and Nickeleit V. The fate of C4d positive kidney allografts lacking histological signs of acute rejection. Clin Nephrol 65 3 (2006) 173. This study showed that deposition of C4d with no morphologic evidence of active rejection served as a sign of on-going AMR, which benefits from antirejection therapy.
5. Cai J., and Terasaki P.I. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 66 4 (2005) 334
6. Terasaki P.I., Ozawa M., and Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 7 2 (2007) 408. This large-scale multicenter prospective study not only demonstrated the association between graft failure and HLA and MICA antibodies but also showed the importance of antibody specificities and strength determination in predicting graft survival.
7. Terasaki P.I., and Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 80 9 (2005) 1194
8. Terasaki P.I., and Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 4 3 (2004) 438
9. Mao Q., Terasaki P.I., Cai J., Briley K., Catrou P., Haisch C., and Rebellato L. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 7 4 (2007) 864
10. Worthington J.E., McEwen A., McWilliam L.J., Picton M.L., and Martin S. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 83 4 (2007) 398
11. Weinstein D., Braun W.E., Cook D., McMahon J.T., Myles J., and Protiva D. Ultra-late antibody-mediated rejection 30 years after a living-related renal allograft. Am J Transplant 5 10 (2005) 2576. This study showed a renal graft recipient who started to develop antibodies 22 years post-transplantation and experienced AMR at the 30th year.
12. Pei R., Lee J.H., Shih N.J., Chen M., and Terasaki P.I. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75 1 (2003) 43
13. Cai J., and Terasaki P.I. Human leukocyte antigen antibodies for monitoring transplant patients. Surg Today 35 8 (2005) 605
14. Terasaki P.I., Lachmann N., and Cai J. Summary of the effect of de novo HLA antibodies on chronic kidney graft failure. Clin Transpl 2006 (2007) 455
15. Lietz K., John R., Burke E., Schuster M., Rogers T.B., Suciu-Foca N., Mancini D., and Itescu S. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Circulation 112 16 (2005) 2468
16. McAlister C.C., Gao Z.H., McAlister V.C., Gupta R., Wright Jr. J.R., MacDonald A.S., and Peltekian K. Protective anti-donor IgM production after crossmatch positive liver-kidney transplantation. Liver Transpl 10 2 (2004) 315
17. Griffiths E.J., Nelson R.E., Dupont P.J., and Warrens A.N. Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival. Transplantation 77 11 (2004) 1771
18. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee J, El-Awar NR, Alberu J: "Natural" HLA antibodies found in non-alloimmunized healthy males. Transplantation, 2008, in press. This study identified natural antibodies in the sera of normal males. These antibodies occur in up to 60% of un-immunized subjects, and the majority seems to target infrequent HLA antigens.
19. Laux G., Mansmann U., Deufel A., Opelz G., and Mytilineos J. A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation 75 9 (2003) 1527
20. Cai J., Terasaki P.I., Mao Q., Pham T., El-Awar N., Lee J.H., and Rebellato L. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 6 12 (2006) 2821
21. Duquesnoy R.J. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 63 5 (2002) 339. This article introduced computer-program-based HLA matching, which is currently widely used in transplant community.
22. Duquesnoy R.J., and Marrari M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum Immunol 63 5 (2002) 353
23. Duquesnoy R.J. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 67 11 (2006) 847
24. Duquesnoy R.J., and Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 68 1 (2007) 12
25. Mao Q., Terasaki P.I., Cai J., El-Awar N., and Rebellato L. Analysis of HLA class I specific antibodies in patients with failed allografts. Transplantation 83 1 (2007) 54
26. Adeyi O.A., Girnita A.L., Howe J., Marrari M., Awadalla Y., Askar M., Martell J., Zeevi A., Shapiro R., Nalesnik M., et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 14 1 (2005) 53
27. El-Awar N., Lee J.H., Tarsitani C., and Terasaki P.I. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Hum Immunol 68 3 (2007) 170
28. Cai J., Kohanof S., and Terasaki P.I. HLA DR antibody epitopes. Clin Transpl 2006 (2007) 103
29. Deng C.T., El-Awar N., Ozawa M., Cai J., Lachmann N., and Terasaki P.I. Human Leukocyte Antigen Class II DQ Alpha and Beta Epitopes Identified From Sera of Kidney Allograft Recipients. Transplantation 86 3 (2008) 452
30. El-Awar N., Terasaki P.I., Cai J., Deng C.T., Ozawa M., and Nguyen A. Epitopes of the HLA-A, B, C, DR, DQ and MICA antigens. Clin Transpl 2007 (2008) 175. This report summarized HLA class I and class II and MICA antibody epitopes which were identified by analyzing antibody profiles of allosera. Some of the epitopes were proved using absorption and elution techniques with single antigen cell lines.
31. El-Awar N.R., Akaza T., Terasaki P.I., and Nguyen A. Human leukocyte antigen class I epitopes: update to 103 total epitopes, including the C locus. Transplantation 84 4 (2007) 532
32. Jordan S.C., Vo A.A., Tyan D., Nast C.C., and Toyoda M. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 9 3 (2005) 408
33. Kaczmarek I., Deutsch M.A., Sadoni S., Brenner P., Schmauss D., Daebritz S.H., Weiss M., Meiser B.M., and Reichart B. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant 26 5 (2007) 511
34. Locke J.E., Zachary A.A., Haas M., Melancon J.K., Warren D.S., Simpkins C.E., Segev D.L., and Montgomery R.A. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 7 4 (2007) 842
35. Nickeleit V., and Andreoni K. The classification and treatment of antibody-mediated renal allograft injury: where do we stand?. Kidney Int 71 1 (2007) 7
36. Sun Q., Liu Z.H., Cheng Z., Chen J., Ji S., Zeng C., and Li L.S. Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil. Kidney Int 71 1 (2007) 24
37. Tyden G., Kumlien G., and Efvergren M. Present techniques for antibody removal. Transplantation 84 12 Suppl (2007) S27